BioAtla, Inc. (BCAB) stock
Close on Oct 19, 2026Market cap $2.18MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $2.18M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$31.45M
- EPS, diluted
- -$25.63
- Book value per share
- -$21.81
- Diluted shares
- 2M
Trading
- Previous close
- $1.36
- Open
- $1.22
- Day's range
- $1.22 – $1.31
- Volume
- 2,183
- Average volume (20 days)
- 8,322
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | BCAB | S&P 500 | Difference | BCAB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -26.8% | +0.6% | −27.4 pts | ||
| 3 months | -66.8% | +3.4% | −70.2 pts | ||
| Year to date | -95.4% | +13.3% | −108.7 pts | ||
| 1 year | -96.8% | +16.6% | −113.5 pts | ||
| 3 years | -98.4% | +86.4% | −184.8 pts | -74.9% | +23.1% |
| 5 years | -99.9% | +81.9% | −181.8 pts | -75.1% | +12.7% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Press releases
Releases BioAtla filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- Results
- Results
- Update
- Results
About BioAtla
Biological Products, (No Diagnostic Substances)
BioAtla is a clinical-stage biopharmaceutical company that discovers and engineers conditionally active antibody therapeutics for the treatment of solid tumor cancers. Utilizing its proprietary Conditionally Active Biologics platform, the company designs therapeutic candidates—including antibody-drug conjugates, bispecific antibodies, and monoclonal antibodies—that selectively target cancer cells in acidic tumor microenvironments while sparing healthy tissues. Key pipeline assets include BA3182, an EpCAM- and CD3-targeting bispecific candidate evaluated in advanced adenocarcinoma, and ozuriftamab vedotin, a ROR2-directed antibody-drug conjugate studied in oropharyngeal squamous cell carcinoma. The firm aims to serve cancer patients by developing oncological therapies that reduce systemic toxicity and expand treatable target antigens.
Company profile, executives and historyBioAtla stock: common questions
What is BioAtla's stock price?
BCAB closed at $1.31 on Oct 19, 2026, down 3.68% on the day.
What is BioAtla's market cap?
BioAtla was worth $2.18M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is BCAB's P/E ratio?
BioAtla lost money over the twelve months to Jun 30, 2026 (diluted EPS -$25.63), so it has no meaningful P/E ratio.
Does BioAtla pay a dividend?
No. BioAtla has not paid a cash dividend over the last twelve months.
How has BCAB stock performed over the past year?
Including dividends, BCAB returned -96.8% over the past year, against +16.6% for the S&P 500.
Who are BioAtla's competitors?
Companies most similar to BioAtla by business, industry and size include CMPX, STRO, INBX, CADL, BDTX.
See a number that looks wrong?